Two biotechnology companies have recently disclosed workforce reductions as they navigate critical decision points. Capricor Therapeutics laid off 10% of its staff to manage operating expenses and focus resources on its Duchenne muscular dystrophy therapy, which awaits an FDA decision. NextCure also underwent significant restructuring, including staff reductions, as it prepares for a merger with Avere Therapeutics. These moves reflect strategic adjustments in response to upcoming regulatory milestones and corporate changes. The companies are positioning themselves for future operations and potential growth.
San Diego, California
https://www.fiercebiotech.com/biotech/capricor-nextcure-shed-light-recent-layoffs